IN2014MN01552A - - Google Patents

Info

Publication number
IN2014MN01552A
IN2014MN01552A IN1552MUN2014A IN2014MN01552A IN 2014MN01552 A IN2014MN01552 A IN 2014MN01552A IN 1552MUN2014 A IN1552MUN2014 A IN 1552MUN2014A IN 2014MN01552 A IN2014MN01552 A IN 2014MN01552A
Authority
IN
India
Prior art keywords
geranylgeranylacetone
alone
mixture
retinal diseases
retinal
Prior art date
Application number
Inventor
KUROSETakahiro
MIYANOTakayuki
KATOMariyo
Yoshihiro Takai
Original Assignee
Rohto Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rohto Pharma filed Critical Rohto Pharma
Publication of IN2014MN01552A publication Critical patent/IN2014MN01552A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A prophylactic ameliorating or therapeutic agent for retinal diseases which comprises geranylgeranylacetone as mentioned in item (a) (b) or (c) below can inhibit the cell death of retinal cells directly to thereby prevent ameliorate or treat retinal diseases radically: (a) a mixture of 5E 9E 13E geranylgeranylacetone with 5Z 9E 13E geranylgeranylacetone wherein 5E 9E 13E geranylgeranylacetone is contained in the mixture in an amount of 80 wt% or more; (b) 5E 9E 13E geranylgeranylacetone alone; and (c) 5Z 9E 13E geranylgeranylacetone alone.
IN1552MUN2014 2012-02-27 2013-02-25 IN2014MN01552A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012040803 2012-02-27
PCT/JP2013/054774 WO2013129315A1 (en) 2012-02-27 2013-02-25 Prophylactic, ameliorating or therapeutic agent for retinal diseases

Publications (1)

Publication Number Publication Date
IN2014MN01552A true IN2014MN01552A (en) 2015-05-08

Family

ID=49082513

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1552MUN2014 IN2014MN01552A (en) 2012-02-27 2013-02-25

Country Status (6)

Country Link
US (2) US20130303625A1 (en)
JP (2) JP5345744B1 (en)
CN (1) CN104136015B (en)
IN (1) IN2014MN01552A (en)
TW (1) TWI566771B (en)
WO (1) WO2013129315A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130303625A1 (en) 2012-02-27 2013-11-14 Rohto Pharmaceutical Co., Ltd. Agent for the prevention, improvement or treatment of retinal disease
WO2014129466A1 (en) * 2013-02-19 2014-08-28 ロート製薬株式会社 Mucosal application agent for preventing, ameliorating or treating retinal disease
JPWO2015029925A1 (en) * 2013-08-26 2017-03-02 ロート製薬株式会社 Retinal disease prevention, amelioration, or treatment
JP6628252B2 (en) * 2014-02-28 2020-01-08 国立大学法人京都大学 Pharmaceutical composition for treatment of ischemic eye disease
CN108998006B (en) * 2018-07-20 2021-06-08 合肥工业大学 An environmentally friendly strain-responsive fluorescent supramolecular material and its preparation method
WO2020081941A1 (en) * 2018-10-19 2020-04-23 Medicinova, Inc. Methods of treating ophthalmic disease/disorder or injury with ibudilast
CN109470534B (en) * 2018-11-12 2021-05-25 山东骏腾医疗科技有限公司 Pathological tissue transparent dewaxing liquid and preparation method thereof
CN109675038A (en) * 2019-02-01 2019-04-26 杭州赫尔斯科技有限公司 Enhance the composition of low concentration atropic category drug safety and clinical efficacy
CN119792302B (en) * 2025-03-14 2025-06-24 山东师范大学 Application of prostaglandin E2 in preparation of medicine for treating retina injury caused by blue light exposure

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06192073A (en) * 1992-12-24 1994-07-12 Eisai Co Ltd Cell differentiation-inducing agent
JP3560072B2 (en) 1994-05-20 2004-09-02 エーザイ株式会社 External base
JPH08133967A (en) * 1994-11-02 1996-05-28 Eisai Co Ltd Agent for treating dry eye
JP2000319170A (en) 1999-03-05 2000-11-21 Eisai Co Ltd Teprenone-containing eye lotion
US20050009772A1 (en) * 2003-05-06 2005-01-13 The Regents Of The University Of California Methods and compositions for the treatment of glaucoma and other retinal diseases
AU2006272586A1 (en) * 2005-07-27 2007-02-01 University Of Florida Research Foundation, Inc. Use of heat shock to treat ocular disease
AU2006272497B2 (en) 2005-07-27 2012-07-19 University Of Florida Research Foundation, Inc. Small compounds that correct protein misfolding and uses thereof
JP2013540720A (en) * 2010-09-01 2013-11-07 コヨーテ・ファーマシューティカルズ・インコーポレイテッド Methods for the treatment of neurodegenerative diseases
US20130303625A1 (en) 2012-02-27 2013-11-14 Rohto Pharmaceutical Co., Ltd. Agent for the prevention, improvement or treatment of retinal disease

Also Published As

Publication number Publication date
JP2013213049A (en) 2013-10-17
TWI566771B (en) 2017-01-21
HK1200111A1 (en) 2015-07-31
US9724312B2 (en) 2017-08-08
CN104136015A (en) 2014-11-05
US20130303625A1 (en) 2013-11-14
CN104136015B (en) 2016-11-09
US20140128475A1 (en) 2014-05-08
JP5345744B1 (en) 2013-11-20
JPWO2013129315A1 (en) 2015-07-30
WO2013129315A1 (en) 2013-09-06
TW201338771A (en) 2013-10-01

Similar Documents

Publication Publication Date Title
IN2014MN01552A (en)
PH12014501718A1 (en) Novel therapeutic agents
PH12016500216A1 (en) Stable pharmaceutical composition and methods of using same
MX370903B (en) Stable percarboxylic acid compositions and uses thereof.
MY185016A (en) Progenitor cells of mesodermal lineage
MY176593A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
MX350432B (en) Therapeutically active compounds and their methods of use.
MX2015013275A (en) Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction.
IN2014DN06104A (en)
BR112014015342A8 (en) induced pluripotent stem cells from cells derived from human umbilical cord tissue
PH12014502805A1 (en) Novel indanesulfamide derivative
TN2013000239A1 (en) New form of administration of enkephalinase inhibitor
MX359002B (en) Method and composition for preventing stem cell disruption and aggregation.
MY171048A (en) Pharmaceutical composition for preventing or treating amyloid beta peptide-associated diseases or conditions
MX2016000294A (en) Pharmaceutical composition for a sustained release of lanreotide.
IN2014MN01551A (en)
PH12015501561A1 (en) Method of treatment of diseases
PH12013501896A1 (en) Use of a sprayable composition comprising ambroxol
WO2014005153A3 (en) Methods for treating mds1-evi1 mediated cancer
PH12015501109A1 (en) Novel compounds as diacylglycerol acyltransferase inhibitors
NZ612843A (en) Pheromone composition
MX342186B (en) Food concentrate in the form of a gel process to prepare the same.
MX337593B (en) Gemcabene and derivatives for treating pancreatitis.
MX353587B (en) Pharmaceutical compositions containing ipidacrine and use thereof to treat potency disorders and other sexual activity disorders.
UA59871U (en) Methods for eliminating consequences of phosphorus spill and neutralization of yellow phosphorus